Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors

Area of Science:

• Endocrinology
• Pharmacology
• HIV Medicine

Background:

• This study reports on four patients experiencing galactorrhoea, an endocrine abnormality, following the use of protease inhibitors (PIs).
• PIs were administered as part of highly active antiretroviral therapy (HAART) for HIV treatment and postexposure prophylaxis (PEP) for HIV prevention.

Discussion:

• The galactorrhoea observed may be a direct consequence of protease inhibitor (PI) usage.
• Alternatively, the endocrine abnormality could be indirectly caused by PIs affecting the cytochrome P450 system.
• This interaction might enhance the dopamine antagonist effects of other concurrently administered medications.

Key Insights:

• Galactorrhoea identified as a potential isolated endocrine side effect of protease inhibitors (PIs).
• Highlights a possible mechanism involving direct PI effects or indirect modulation of drug metabolism via the cytochrome P450 pathway.
• Suggests potentiation of dopaminergic antagonism as a contributing factor.

Outlook:

• Further investigation into the precise mechanisms linking PIs to galactorrhoea is warranted.
• Clinical awareness of this potential endocrine side effect in patients on PIs is crucial for accurate diagnosis and management.
• Exploring alternative antiretroviral or prophylactic regimens may be considered in cases of persistent galactorrhoea.